This action is reminiscent of dimethyl fumarate (DMF), an approved MS therapy, which also downregulates pro-inflammatory cytokines like IL-1β and TNF-α through microglial modulation [87,88]. The gene discussed is TNF; the disease is myeloid sarcoma.